Silence Therapeutics plc (SLNCF) Stock Price & Analysis
Silence Therapeutics plc (SLNCF) — price $4.00 (0.00%), as of the Oct 2, 2026 trading session; market cap $567M.
Educational signal · not a buy or sell recommendation · How to read this
Silence Therapeutics plc · SLNCF
Silence Therapeutics plc is a biotechnology company focused on developing novel RNA therapeutics. Their mRNAi GOLD platform targets disease-associated genes in hematology, cardiovascular, and metabolic indications.
Price as of Oct 2, 2026
Key Statistics
MoonshotScore is not published for this security.
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $4.00 | |
| Change on the day | 0.00% | |
| 52-week range | $1.06 – $5.99 | |
| Market capitalisation | $567M | |
| Shares traded on the day | 100 |
Price & events
Other perspectives
Council score for Silence Therapeutics (SLNCF): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
9-Factor Breakdown
Legends Council
6 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Sep 11, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Sep 9, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Sep 9, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Oct 4, 2026, except a card that shows its own read date.
Watch the SLNCF film — every key number, told as a short cinematic story
~2 min · open the film
What is Silence Therapeutics (SLNCF), and what does it report?
Short answer · as of
A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Silence Therapeutics plc (SLNCF) is the company analyzed here. It employs 88 people and is led by Iain Gladstone Ross. In Q2 FY2026 it reported revenue of $0 and net income of -$12M. The market values it at $567M.
What do the latest results show for Silence Therapeutics (SLNCF)?
Short answer · as of
The most recent reported quarter, Q2 FY2026, carried revenue of $0. Against analyst estimates the company has EPS beat 2 of 8 reports.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q2 FY2026 | $0 | -$12M | -$0.09 (diluted) |
| Q1 FY2026 | $422,000 | -$15M | -$0.11 (diluted) |
| Q4 FY2025 | $34,000 | -$12M | -$0.08 (diluted) |
| Q3 FY2025 | $159,000 | -$21M | -$0.15 (diluted) |
What are the financial strengths and risks for Silence Therapeutics (SLNCF)?
Short answer
The distress and quality screens read Altman Z -5.13 · Piotroski F 1. Trailing ratios: ROA -56.3% · current ratio 7.42 · earnings yield -35.6% · free-cash-flow yield -8.4%.
Data-derived red flags
- Financial-distress signal — its Altman Z-Score of -5.13 sits in the distress zone (elevated bankruptcy risk).
- Inconsistent delivery — missed Wall Street EPS estimates in 6 of the last 8 reported quarters.
- Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
What has been published about Silence Therapeutics (SLNCF)?
- Silence Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional ADSs
- Silence Therapeutics Announces Pricing of Upsized $175 Million Underwritten Public Offering
- Silence Therapeutics’ Divesiran Hits Phase II Goal, Sets Up Phase III PV Trial
- Silence Therapeutics Announces Proposed Public Offering of $150 Million of American Depositary Shares
Investor Questions: SLNCF Stock
These answers are editorial: 1 of these 8 answers is drawn from the SLNCF research dossier (written Mar 17, 2026 by gemini-2.0-flash); the other 7 are question templates that restate figures shown above. Figures in this section are not part of the source register.
Is SLNCF a good stock to buy?
Stock Expert AI does not rate SLNCF buy, sell or hold. Silence Therapeutics plc has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the SLNCF stock price today?
The last price recorded on this page for Silence Therapeutics plc (SLNCF) is $4.00, as of the Oct 2, 2026 trading session (source: Financial Modeling Prep (FMP) · quote). It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What do analysts say about SLNCF stock?
Analyst coverage of SLNCF stock is limited due to its OTC listing and relatively small market capitalization. However, analysts generally view Silence Therapeutics' RNA therapeutic platform and clinical pipeline as promising.
What are the key factors to evaluate for SLNCF?
Evaluate SLNCF on fundamentals, analyst consensus, and risk factors. Collaboration agreements with AstraZeneca, Mallinckrodt, and Hansoh Pharmaceutical provide financial support and validation of the company's technology. Not financial advice.
How frequently does SLNCF data refresh on this page?
SLNCF's price is the last quote we recorded, from the Oct 2, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven SLNCF's recent stock price performance?
Silence Therapeutics plc (SLNCF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary mRNAi GOLD platform for targeted RNA interference. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider SLNCF overvalued or undervalued right now?
Silence Therapeutics plc (SLNCF) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research SLNCF before investing?
Before investing in Silence Therapeutics plc (SLNCF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 17, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources — records for every figure on this page (14 figures)
The 14 rows below are exactly the facts the evidence-backed sections of this page printed — the 10-second verdict, the MoonshotScore, price and market value, the five questions with their receipts, and the records behind this page. Known dates and sources are recorded on their own rows; an em dash or UNRECORDED tier preserves a stored observation without inventing either. The quarterly income statement is provider-standardized (FMP) under one row, and scale definitions — a 0-100 rating, the band ladder, the Piotroski 0–9 range — are fixed rather than measured. No number in those sections was generated by a model. The register does not cover quoted third-party headlines, the dated council readings, or the Frequently Asked Questions; each of those says where it came from where it stands.
"As of" is the date the value is true for where the source carries one — a quarter end, a filing date, a price close, the day the score was computed. A cached observation with no source date remains undated; the page publication date is not used as a substitute.
FMP — 8 facts from Financial Modeling Prep endpoint families
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
px.last | Latest provided price | $4.00 | FMP | Financial Modeling Prep (FMP) · quote — Dated to the US trading session the price belongs to, derived from the quote record's timestamp (weekend and pre-open reads roll back to the previous weekday; exchange holidays are not modelled). The record does not establish an exchange execution time. Retrieved 2026-10-04T21:04:44.297Z. | |
px.change | Change on the day | 0.00% | FMP | Financial Modeling Prep (FMP) · quote | |
px.mcap | Market capitalisation | $567M | FMP | Financial Modeling Prep (FMP) · quote — Date unknown Market cap record date: 2026-10-02. FMP quote timestamp: 2026-10-02T20:00:00.000Z. Captured from FMP at 2026-10-04T21:04:43.043Z. No share-count basis is inferred; this page preserves the reported amount instead of recalculating it from shares. | |
px.change_abs | Change on the day, in dollars | $0.00 | FMP | Financial Modeling Prep (FMP) · quote | |
px.volume | Shares traded on the day | 100 | FMP | Financial Modeling Prep (FMP) · quote | |
fin.q_revenue | Revenue, Q2 FY2026 | $0 | FMP | Financial Modeling Prep (FMP) · income statement (quarterly) | |
fin.q_income | Net income, Q2 FY2026 | -$12M | FMP | Financial Modeling Prep (FMP) · income statement (quarterly) | |
fin.q_table | Quarterly income statement | 4 quarters through Q2 FY2026 | FMP | Financial Modeling Prep (FMP) · income statement (quarterly), as filed |
UNRECORDED — 6 facts from stored observations whose source was not recorded
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
px.range52 | 52-week range | $1.06 – $5.99 | UNRECORDED | Stored company-profile observation — Captured 2026-09-27 · Expired observation | |
id.employees | Employees | 88 | UNRECORDED | Stored company-profile observation — Captured 2026-09-27 · Expired observation | |
id.ceo | Chief executive | Iain Gladstone Ross | UNRECORDED | Stored company-profile observation — Captured 2026-09-27 · Expired observation | |
earn.history | Reported versus estimated, recent quarters | EPS beat 2 of 8 | UNRECORDED | Stored earnings-history observation — Captured 2026-09-12 · Expired observation | |
fin.scores | Distress and quality screens | Altman Z -5.13 · Piotroski F 1 | UNRECORDED | Stored financial-scores observation — Captured 2026-10-03 · Expired observation | |
fin.ratios | Return and yield ratios (trailing twelve months) | ROA -56.3% · current ratio 7.42 · earnings yield -35.6% · free-cash-flow yield -8.4% | — | UNRECORDED | Stored key metrics — Date unknown |
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com
Data provided for informational purposes only.